PhD Thesis_ver3.pdf

VII. БИБЛИОГРАФИЯ
1. Abe, M., K. Hiura, J. Wilde, A. Shioyasono, K. Moriyama, et al. (2004). "Osteoclasts enhance
myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone
destruction and myeloma expansion." Blood 104(8): 2484-91.
2. Aggarwal, B. B., A. Kumar and A. C. Bharti (2003). "Anticancer potential of curcumin: preclinical
and clinical studies." Anticancer Res 23(1A): 363-98.
3. Aggarwal, B. B. and S. Shishodia (2004). "Suppression of the nuclear factor-kappaB activation
pathway by spice-derived phytochemicals: reasoning for seasoning." Ann N Y Acad Sci 1030:
434-41.
4. Aggarwal, R., I. M. Ghobrial and G. D. Roodman (2006). "Chemokines in multiple myeloma." Exp
Hematol 34(10): 1289-95.
5. Aggarwal, S., H. Ichikawa, Y. Takada, S. K. Sandur, S. Shishodia, et al. (2006). "Curcumin
(diferuloylmethane) down-regulates expression of cell proliferation and antiapoptotic and
metastatic gene products through suppression of IkappaBalpha kinase and Akt activation."
Mol Pharmacol 69(1): 195-206.
6. Agresta, M., P. D'Arrigo, E. Fasoli, D. Losi, G. Pedrocchi-Fantoni, et al. (2003). "Synthesis and
antiproliferative activity of alkylphosphocholines." Chem Phys Lipids 126(2): 201-10.
7. Alaikov, T., S. M. Konstantinov, T. Tzanova, K. Dinev, M. Topashka-Ancheva, et al. (2007).
"Antineoplastic and anticlastogenic properties of curcumin." Ann N Y Acad Sci 1095: 355-70.
8. Amundson, S. A., T. G. Myers, D. Scudiero, S. Kitada, J. C. Reed, et al. (2000). "An informatics
approach identifying markers of chemosensitivity in human cancer cell lines." Cancer Res
60(21): 6101-10.
9. Andreesen, R., M. Modolell, H. U. Weltzien, H. Eibl, H. H. Common, et al. (1978). "Selective
destruction of human leukemic cells by alkyl-lysophospholipids." Cancer Res 38(11 Pt 1):
3894-9.
10. Aoki, H., Y. Takada, S. Kondo, R. Sawaya, B. B. Aggarwal, et al. (2007). "Evidence that curcumin
suppresses the growth of malignant gliomas in vitro and in vivo through induction of
autophagy: role of Akt and extracellular signal-regulated kinase signaling pathways." Mol
Pharmacol 72(1): 29-39.
11. Armand, J. P., A. K. Burnett, J. Drach, J. L. Harousseau, B. Lowenberg, et al. (2007). "The emerging
role of targeted therapy for hematologic malignancies: update on bortezomib and tipifarnib."
Oncologist 12(3): 281-90.
12. Arndt, D., R. Zeisig, I. Eue, B. Sternberg and I. Fichtner (1997). "Antineoplastic activity of sterically
stabilized alkylphosphocholine liposomes in human breast carcinomas." Breast Cancer Res
Treat 43(3): 237-46.
13. Attal, M., J. L. Harousseau, S. Leyvraz, C. Doyen, C. Hulin, et al. (2006). "Maintenance therapy with
thalidomide improves survival in patients with multiple myeloma." Blood 108(10): 3289-94.
14. Attal, M., J. L. Harousseau, A. M. Stoppa, J. J. Sotto, J. G. Fuzibet, et al. (1996). "A prospective,
randomized trial of autologous bone marrow transplantation and chemotherapy in multiple
myeloma. Intergroupe Francais du Myelome." N Engl J Med 335(2): 91-7.
15. Au, W. Y. and Y. L. Kwong (2008). "Arsenic trioxide: safety issues and their management." Acta
Pharmacol Sin 29(3): 296-304.
16. Badros, A. Z., O. Goloubeva, A. P. Rapoport, B. Ratterree, N. Gahres, et al. (2005). "Phase II study
of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and
thalidomide in relapsed multiple myeloma patients." J Clin Oncol 23(18): 4089-99.
17. Bagchi, D. and H. G. Preuss (2005). Phytopharmaceuticals in cancer chemoprevention. Boca
Raton, Fla., CRC Press: 665 p., [4] colored plates.
311